Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, announced that Shin Oh, MD, one of its clinical investigators, will be making an oral presentation of safety and efficacy data from the Firdapse® Phase 3 clinical trial in patients with Lambert-Eaton myasthenic syndrome (LEMS) at the American Academy of Neurology (AAN) 67th Annual Meeting. The AAN meeting will be held April 18 to 25, 2015, in Washington, DC.

The oral presentation titled, “Amifampridine phosphate (Firdapse®) is safe and effective in a pivotal Phase 3 trial in LEMS patients” will be given during the Clinical Trials Plenary Session on Friday, April 24, 12:00 pm-1:30 pm. This session was designed by the AAN to address important clinical topics identified throughout the neurology community that affect patient care, and the Science Committee considered the Firdapse® Trial results an advancement in the field of autoimmune disease and neuroscience.

“LEMS is a very rare autoimmune disorder with debilitating muscle weakness and other severe symptoms,” stated Dr. Shin Oh, Distinguished Professor Emeritus at the University of Alabama-Birmingham and invited presenter at the AAN conference. “The statistically significant and clinically relevant outcomes of primary and secondary endpoints of the Firdapse® pivotal Phase 3 trial demonstrate the potential for Firdapse® to help patients with this severely disabling disease.”

“We are pleased that Dr. Oh has been invited to the AAN conference to present the data from our successful Phase 3 Firdapse® trial to an audience of neuromuscular disease specialists and neurologists,” stated Patrick J. McEnany, President and CEO of Catalyst. “I would like to once again thank all the patients and physicians who participated in this Phase 3 trial as we continue to work towards the approval of Firdapse®.”

Catalyst Pharmaceuticals will also be exhibiting during the AAN meeting in the Main Exhibit Hall at booth #1735, from Monday April 20th to Thursday April 23rd(Original Source)

Shares of Catalyst closed yesterday at $4.69 . CPRX has a 1-year high of $5.10 and a 1-year low of $1.70. The stock’s 50-day moving average is $4.22 and it’s 200-day moving average is $3.23.

On the ratings front, Catalyst has been the subject of a number of recent research reports. In a report issued on February 17, Piper Jaffray analyst Charles Duncan reiterated a Buy rating on CPRX, with a price target of $7, which represents a potential upside of 49.3% from where the stock is currently trading. Separately, on February 2, Roth Capital’s Scott Henry reiterated a Buy rating on the stock and has a price target of $6.

According to, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Charles Duncan and Scott Henry have a total average return of 13.7% and 35.5% respectively. Duncan has a success rate of 55.6% and is ranked #603 out of 3574 analysts, while Henry has a success rate of 65.7% and is ranked #25.

Catalyst Pharmaceutical Partners Inc is a development-stage biopharmaceutical company focused on the development and commercialization of prescription drugs targeting rare (orphan) neurological diseases and disorders.